T-DXd: New Standard for HER2-Low Breast Cancer

Abstract Findings from the phase III DESTINY-Breast04 trial indicate that the antibody–drug conjugate trastuzumab deruxtecan (T-DXd) is effective for patients with inoperable/metastatic HER2-low breast cancer. T-DXd should be considered a new standard of care for these patients, who otherwise have limited options.